Marken Leads Logistics Industry In Gene And Cell Therapy Trials

USA - Deutsch

USA - Français

Company Presents a Case Study at Barcelona Conference

News provided by

Oct 01, 2015, 07:49 ET

RESEARCH TRIANGLE PARK, N.C., Oct. 1, 2015 /PRNewswire/ -- Marken announced this week details of a case study presented at a key Barcelona conference which demonstrates its expertise in handling patient-specific gene or cell therapy-based clinical trials.

Marken presented a case study at the Cell & Gene Therapy Europe Conference in Barcelona which focused on a global, multi-centered cell-based therapy trial involving nearly 1000 patients in over 20 countries. The trial requires shipments of bio-hazardous material derived from patient samples, which are transported in liquid nitrogen containers but must reach the manufacturing site within 28 hours of the patient visit. The logistics of preparing the samples, transporting them across country borders, delivering them within stability, manufacturing a patient-specific vaccine and finally delivering the treatment to a patient are a complex undertaking.

These gene or cell based, bio-hazardous materials require special handling under cryogenic conditions. More importantly, the regulations for handling the shipments can vary from country to country which makes supply chain planning a highly specialized service. Marken's broad network and expertise help clients to define and mitigate risks when planning their clinical trials.

"We see a continuing increase in requests for gene and cell therapy trials and will continue to invest in our infrastructure by expanding our transport and storage using liquid nitrogen shippers at minus180 degrees Celsius. We believe we are the first logistics company to offer liquid nitrogen storage capabilities for clinical trials on a global scale," said Wes Wheeler, CEO of Marken. "We are combining the company's expansive logistics expertise with a global network of GMP compliant depots to create the perfect platform of services to support time and temperature-critical, gene and cell therapy supply chains."

More details and questions about shipping setting up the supply chain for gene and cell therapy trials can be directed to Marken's experts at [email protected]

About Marken
Marken is the only patient centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to patient services and biological sample shipments and offers a state of the art GMP compliant depot network and logistic hubs in 42 locations worldwide. Marken's 630 staff members manage 50 000 drug and biological shipments every month at all temperature ranges in more than 150 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane qualifications, as well as GDP, regulatory and compliance consultancy add to Marken's unique position in the Pharma and Logistics industry.

www.marken.com

Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO

SOURCE Marken